M&A Deal Summary

Mallinckrodt Acquires Sucampo Pharmaceuticals

On December 26, 2017, Mallinckrodt acquired life science company Sucampo Pharmaceuticals for 1.2B USD

Acquisition Highlights
  • This is Mallinckrodt’s 8th transaction in the Life Science sector.
  • This is Mallinckrodt’s 5th largest (disclosed) transaction.
  • This is Mallinckrodt’s 11th transaction in the United States.
  • This is Mallinckrodt’s 1st transaction in Maryland.

M&A Deal Summary
Date 2017-12-26
Target Sucampo Pharmaceuticals
Sector Life Science
Buyer(s) Mallinckrodt
Deal Type Add-on Acquisition
Deal Value 1.2B USD
Advisor(s) Jefferies (Financial)
Cooley (Legal)

Target

Sucampo Pharmaceuticals

Bethesda, Maryland, United States
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Mallinckrodt

Dublin, United Kingdom
Category Company
Founded 1867
Sector Life Science
Employees2,673
Revenue 2.2B USD (2021)
DESCRIPTION

Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.

DEAL STATS #
Overall 11 of 12
Sector (Life Science) 8 of 9
Type (Add-on Acquisition) 10 of 10
State (Maryland) 1 of 1
Country (United States) 11 of 11
Year (2017) 3 of 3
Size (of disclosed) 5 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-11-02 Ocera Therapeutics

Palo Alto, California, United States

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (IV) and oral formulations. OCR-002 is an ammonia scavenger and has been granted Orphan Drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and acute-on-chronic liver disease.

Buy $42M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-03-19 Mallinckrodt - Recothrom and Preveleak

Dublin, Ireland

Mallinckrodt plc - Recothrom and Preveleak is a provider of stand-alone recombinant thrombin and Surgical Sealant is used in vascular reconstruction.

Sell -
Mergr

Product

Company

Legal